home

OncoArendi Therapeutics Announces Selection of Its First Clinical Development Candidate for the Treatment of Asthma

R&DPharmacodia.com2015-10-15 00:00 Read   275

October 13, 2015 I On October 13, 2015, OncoArendi Therapeutics Ltd. announced that it selected OATD-01 as its clinical development candidate for the treatment of asthma.

DBV Technologies Announces First Patient Enrolled in Phase II Study of Viaskin Milk

R&DPharmacodia.com2015-10-15 00:00 Read   317

DBV Technologies announced that it has begun enrolling cow's milk-allergic subjects in the Part B (Phase II) of the MILES Phase I/II study (Viaskin MILk Efficacy and Safety).

Dermira Completes Patient Enrollment for First CIMZIA(R) (Certolizumab Pegol) Phase 3 Clinical Trial in Psoriasis Program

R&DPharmacodia.com2015-10-14 00:00 Read   380

 October 12, 2015, Dermira, Inc. (DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the completion of patient enrollment for the global CIMPASI-2 clinical trial of CIMZIA(R) (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis.

Alder BioPharmaceuticals Initiates Pivotal Clinical Trial of ALD403 for Preventative Treatment of Frequent Episodic Migraine

R&DPharmacodia.com2015-10-14 00:00 Read   370

October 13, 2015, Alder BioPharmaceuticals, Inc. (“Alder”) (ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, Cushing’s disease

Company Releases Financial Releases Product Releases Archived Releases2015201420132012201120102009200820072006 Media Inquiries Fact Sheets Email Alerts Significant Improvements in Skeletal Mineralization and Physical Function Observed in Children with Hypophosphatasia (HPP) Treated With Strensiq™ (asfotase alfa) Sustained for at least Five Years

R&DPharmacodia.com2015-10-14 00:00 Read   524

October 12, 2015, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers presented new data from the extension phase of an ongoing, open-label Phase 2 study in children with hypophosphatasia (HPP) who were treated with Strensiq™ (asfotase alfa) for at least five years.

Zosano Pharma Announces Positive Phase 2 Results for Its ZP-Glucagon Patch Program for Treatment of Severe Hypoglycemia

R&DPharmacodia.com2015-10-14 00:00 Read   435

October 13, 2015, Zosano Pharma Corporation (ZSAN), a clinical-stage specialty pharmaceutical company, today announced positive results from the Phase 2 clinical trial of its proprietary, rapid onset, transdermal ZP-Glucagon patch for severe hypoglycemia.

Intec Pharma Announces Topline Results of a Food Effect, Pharmacokinetic Study of AP-CDLD 50/500mg for the Treatment of Parkinson's Disease Symptoms

R&DPharmacodia.com2015-10-14 00:00 Read   317

Intec Pharma Announces Topline Results of a Food Effect, Pharmacokinetic Study of AP-CDLD 50/500mg for the Treatment of Parkinson's Disease Symptoms

Theravance Biopharma Submits Investigational New Drug (IND) Application for TD-0714, an Inhibitor of Neprilysin (NEP)

R&DPharmacodia.com2015-10-14 00:00 Read   224

Phase 1 Trial of Potential Best-in-Class Neprilysin Inhibitor Planned for Q4 2015; Compound Designed for Broad Use in Major Cardiovascular and Renal Diseases

Rebiotix Receives Breakthrough Therapy Designation for RBX2660 -- A Microbiota Restoration Therapy (MRT) for the Treatment of Recurrent Clostridium difficile Infection

R&DPharmacodia.com2015-10-13 00:00 Read   479

October 12, 2015, Rebiotix Inc. today announced that U.S. Food and Drug Administration (FDA) has designated its lead Microbiota Restoration Therapy (MRT) RBX2660 as a Breakthrough Therapy for the treatment of recurrent Clostridium difficile (C diff) infection.

Biodel Announces Removal of Partial Clinical Hold for BIOD-531 and Plans for Potential Expansion of Target Patient Population

R&DPharmacodia.com2015-10-13 00:00 Read   366

October 12, 2015, Biodel Inc. (BIOD) today announced that the United States Food and Drug Administration (FDA) has removed the partial clinical hold for Biodel's previously initiated Phase 2b Study 3-250.

Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease

R&DPharmacodia.com2015-10-13 00:00 Read   224

October 12, 2015, Eli Lilly and Company (NYSE: LLY) and the ACCELERATE study's academic leadership have accepted the recommendation of the independent data monitoring committee to terminate the Phase 3 trial of the investigational medicine evacetrapib.

One Year Data from Phase III Study Evaluating Oral OTEZLA® (apremilast) or Injectable etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at EADV

R&DPharmacodia.com2015-10-13 00:00 Read   227

October 12 2015, Celgene International Sàrl, a wholly owned subsidiary of Celgene 52 of Corporation (NASDAQ: CELG), today announced that results from its ongoing phase III LIBERATE™ trial evaluating Otezla (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with moderate to severe plaque psoriasis were presented as a late-breaker at the 24th European Academy of Dermatology and Venereology (EADV) Congress in Copenhagen, Denmark, October 7-11, 2015.